Tag Archives: BME

Best Performing Stocks For 2021

Why is the dollar so weak even as Treasury yields are on the rise? Some economists argue that the blame lies with the twins.

No, not the starkly contrasting, fraternal twins who were separated at birth in the 1988 film Twins, featuring Arnold Schwarzenegger and Danny DeVito.

Rather the additional fiscal boost to the U.S. economy coming from the tax cuts signed into law late last year by President Donald Trump and a two-year budget deal, which are expected to deepen the budget deficit and the current-account deficita combo termed the twin deficits.

Best Performing Stocks For 2021: STERIS Corporation(STE)

STERIS Corporation and its subsidiaries develop, manufacture, and sell infection prevention, contamination control, microbial reduction, and surgical support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. It provides steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers; liquid chemical sterilant processing systems; washer/disinfector systems; general and specialty surgical tables; surgical and examination lights; equipment management systems; operating room storage cabinets; warming cabinets; scrub sinks; and other products and accessories. The company also offers connectivity solutions, such as operating room integration, workflow, patient tracking, and instrument management that allow transfer of information and images; cleaning chemistries and sterility assurance products; cleansing products, including hard surface disinfectants, and skin care and hand hygiene solutions; high-pu rity water equipment; vaporized hydrogen peroxide generators. In addition, it sells contract materials processing services using gamma irradiation and ethylene oxide technologies, as well as offers microbial reduction services based on customer specifications. Further, the company provides maintenance programs and repair services, sterilization and surgical management consulting services, information management and decision support services, and other support services, such as construction and facility planning, engineering support, device testing, customer education, hand hygiene process excellence, asset management/planning, and the sale of replacement parts. STERIS Corporation sells its products to end users, dealers, and distributors through direct field sales and service representatives. The company was formerly known as Innovative Medical Technologies and changed its name to STERIS Corporation in 1987. STERIS Corporation was founded in 1985 and is headquartered in Ment or, Ohio.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Steris Corp (NYSE:STE)Q32019 Earnings Conference CallFeb. 12, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Stephan Byrd]

    Shares of Steris PLC (NYSE:STE) have received a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $98.00.

  • [By Stephan Byrd]

    Shares of Steris PLC (NYSE:STE) have been given an average recommendation of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $98.00.

Best Performing Stocks For 2021: Blackrock Health Sciences Trust(BME)

BlackRock Health Sciences Trust (the Trust) is a non-diversified, closed-end management investment company. The Trusts investment objective is to provide total return through a combination of current income and capital appreciation. BlackRock Health Sciences Trust seeks to achieve this objective by investing primarily in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. Trust will invest at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry.

BlackRock Health Sciences Trust invests in various sectors, which include pharmaceuticals, healthcare products, biotechnology, healthcare services, electronics, retail and distribution/wholesale. It operates in countries, such as United States, Switzerland, China, France, Germany, Canada and United Kingdom.

Advisors’ Opinion:

  • [By Logan Wallace]

    Shares of BME traded up $0.60 during midday trading on Monday, hitting $40.92. The company had a trading volume of 34,700 shares, compared to its average volume of 35,130. Blackrock Health Sciences Trust has a 52 week low of $32.00 and a 52 week high of $44.00.

    TRADEMARK VIOLATION WARNING: “Blackrock Health Sciences Trust Declares Monthly Dividend of $0.20 (BME)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at www.tickerreport.com/banking-finance/4125742/blackrock-health-sciences-trust-declares-monthly-dividend-of-0-20-bme.html.

    About Blackrock Health Sciences Trust

  • [By Logan Wallace]

    Shares of B&M European Value Retail SA (LON:BME) have been assigned an average recommendation of “Buy” from the sixteen research firms that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is GBX 451.36 ($5.88).

  • [By Max Byerly]

    B&M European Value Retail (LON:BME) had its target price boosted by analysts at HSBC from GBX 470 ($6.26) to GBX 500 ($6.66) in a report released on Wednesday. The brokerage presently has a “buy” rating on the stock. HSBC’s price objective indicates a potential upside of 21.54% from the company’s current price.

Best Performing Stocks For 2021: NovoCure Limited(NVCR)

NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.

Advisors’ Opinion:

  • [By Brian Feroldi]

    Medical device makers were some of the best-performing companies on the market last year. In this week’s episode of Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Brian Feroldi talk about three medical device monopolies that investors might want to take a closer look at. Listen and find out what makes Intuitive Surgical(NASDAQ:ISRG), Abiomed(NASDAQ:ABMD), and NovoCure (NASDAQ:NVCR)stand out from the crowd, dominate their niches, and improve patient lives. Plus, learn the key metrics investors should watch, what long-term risks to be aware of, which of the companies faces the most competitive risk, some of the most exciting opportunities still ahead, and more.

  • [By Ethan Ryder]

    Novocure (NASDAQ:NVCR) and Anika Therapeutics (NASDAQ:ANIK) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

  • [By Beth McKenna]

    Novocure Ltd. (NASDAQ:NVCR) stock jumped 16.3% in September, according to data fromS&P Global Market Intelligence. For context, theS&P 500 returned0.6% last month.

Best Performing Stocks For 2021: Express Scripts Holding Company(ESRX)

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States, Canada, and Europe. The company operates through two segments, PBM and Other Business Operations. The companys PBM segments products and services include clinical solutions to enhance health outcomes; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services, including design, implementation, and project management for pharmaceutical, biotechnology, and device manufacturers to collect scientific evidence to guide the use of medicines. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2015, the company operated four automated dispensing home delivery pharmacies; one non-automated dispensing home delivery pharmacy; and one non-dispensing home delivery pharmacy maintained for business continuity purpose, as well as several non-dispensing order processing centers, patient contact centers, specialty drug pharmacies, and fertility pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

Advisors’ Opinion:

  • [By Shane Hupp]

    Bank of Stockton raised its holdings in Express Scripts Holding Co (NASDAQ:ESRX) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,821 shares of the company’s stock after buying an additional 581 shares during the period. Bank of Stockton’s holdings in Express Scripts were worth $1,123,000 as of its most recent SEC filing.

  • [By Brian Orelli]

    Discounts off the list price vary widely from disease to disease, but they’re largely tied to how many competitors there are in the space. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE:ABBV), which sells Mavyret and Viekira Pak, they can get steeper discounts than if there’s only one superior medication to treat a disease. A few years ago, in protest to the lack of negotiation, PBM Express Scripts (NASDAQ:ESRX) was only covering AbbVie’s drug for a while, and Express Scripts has removed drugs in other diseases from its formulary for playing hardball on negotiations.

  • [By Todd Campbell]

    Its lackluster launch isn’t a secret, though, and now that its cardiovascular outcomes study has shown it lowers the risk of cardiovascular events including heart attack, stroke, and death, its sales are beginning to perk up. The FDA hasn’t approved adding the outcomes data to Praluent’s prescribing label yet (a decision is expected next April), but that hasn’t stopped doctors from prescribing it more frequently, or payers from dropping barriers to its access. In Q2, Praluent’s revenue was $73.5 million, a nearly $300 million annualized sales run rate, up from $46.1 million in the same quarter last year. Importantly, a deal with the nation’s second-largest pharmacy benefit manager, Express Scripts (NASDAQ:ESRX), makes it the preferred drug in its class for Express Scripts patients beginning in July, and that should provide a nice sales boost from here.

  • [By Demitrios Kalogeropoulos]

    Express Scripts Holding Company (NASDAQ:ESRX) outpaced the market by gaining 11% last month compared to a 3% jump in the S&P 500, according to data provided by S&P Global Market Intelligence.